麻豆传媒

OB/Gyn >

Ovarian Cancer

News, opinions and meeting coverage in obstetrics and gynecology.

Does Johnson's Baby Powder Cause Cancer?

Milton Packer says the $4.69-billion verdict is about anger, not medicine

Simple Ovarian Cysts Hold No Cancer Risk

Malignancy extremely rare, don't need surveillance

Practice-Changing PARP Inhibitor Study in Ovarian Cancer

"Unprecedented" increase in PFS with upfront olaparib maintenance

Cancer Linked to Infertility in Men and Women

Assisted reproductive technology not to blame, researchers say

PFS Rises in Ovarian Ca with Repeat Bevacizumab

Magnitude of benefit similar to first-line therapy

Women Do Well Without Opioids after Gyn Surgery

An 89% drop in opioid use with restrictive prescribing protocol

Gyn Cancer Research Gets Short Shrift in Funding

Mortality-adjusted analysis shows huge disparity versus other cancers

Possible Chlamydia Link with Ovarian Cancer

Associations seen in two separate cohorts of women

Telemedicine OK for Genetic Testing and Counseling

Trial finds no major difference in psychosocial outcomes

No Survival Benefit with Node Dissection in Ovarian Ca

Macroscopic complete resection drives outcomes

Advanced Ca Patients Benefit from Online Symptom Reports

Patient-reported outcomes tied to increased survival

Second Surgery Slows Recurrent Ovarian Cancer

But no survival gain seen in interim analysis of DESKTOP III

HPV-Targeted Drug Sets Survival Mark in Cervical Cancer

Highest-ever 12-month survival in recurrent, metastatic disease

MSK Cancer Alliance: Mainly About Medicine

Bi-directional relationship strengthens regional cancer care

Frankie the Dog Fetches - and Finds Thyroid Cancer?

Canine trained in cancer scent detection gives few false positives in early test.

FDA Panel Puts Brakes on Anti-PARP Drug

WASHINGTON -- Approval of a PARP inhibitor for patients with advanced ovarian cancer should await results of an ongoing clinical trial that has the potential to answer questions about the drug's safety and efficacy, according to an FDA advisory committee that voted against immediate approval.

ASCO: Targeted Combo Extends PFS in Ovarian Ca

CHICAGO -- Progression-free survival almost doubled in women with platinum-sensitive relapsed ovarian cancer treated with two targeted drugs instead of one, investigators reported here.

Anti-PARP Tx Works in Advanced Ovarian Cancer

TAMPA, Fla. -- Advanced ovarian cancer treated with PARP inhibitor maintenance therapy had significant improvement in progression-free survival, extending beyond first progression, investigators reported.

Cancer Ascites Responds to Outpatient Tx

TAMPA, Fla. -- Outpatient treatment of malignant ascites with a monoclonal antibody proved safe and feasible and led to a survival benefit in gynecologic cancer patients who could receive chemotherapy, a small clinical study showed.

Medicare to Pay for More FDG-PET Scans

WASHINGTON -- Up to three scans using 18F-fluorodeoxyglucose-enhanced positron emission tomography technology can be covered by Medicare for oncology treatment planning, the Centers for Medicare and Medicaid Services said.

ASCO: Vinegar Test May Reduce Cervical Ca Deaths

CHICAGO -- Vinegar has been used for everything from cleaning refrigerators to taming foot odors, and now this common kitchen staple may reduce cervical cancer deaths as well, researchers reported here.

ASCO: Targeted Rx Slows Ovarian Ca Progression

CHICAGO -- Adding the oral anti-angiogenesis drug pazopanib (Votrient) to chemotherapy extended disease-free survival by an average of 5.6 months, a phase III study showed.

Doctors Say 45 Common Tests 'Overused'

Nine specialty groups have listed tests and treatments that are frequently overused, such as antibiotics for sinus attacks and CT scans for low back pain, in the first phase of a long-term project.

ASCO: Abagovomab No Help in Ovarian Cancer

CHICAGO -- Results from a study using the experimental monoclonal antibody drug abagovomab to protect women with advanced ovarian cancer from recurrence have been disappointing, researchers reported here.

ASCO: Targeted Agent Slows Recurrent Ovarian Cancer

CHICAGO -- Women with recurrent platinum-sensitive ovarian cancer had a 50% improvement in progression-free survival when bevacizumab (Avastin) was added to chemotherapy, results of a multicenter randomized trial showed.

SGO: Low Cancer Risk with Septated Ovarian Tumors

SAN FRANCISCO -- Septated ovarian tumors have a low risk of malignancy and can be followed safely with ultrasound, data from a large prospective cohort study showed.